Prof. Dr. Gökmen Umut ERDEM

1. Clinicopathological Factors Influencing Survival After Trimodality Treatment in Non-Metastatic Esophageal Cancer: A Retrospective Single-Center Study

Yakin M., BULUT N., Kapagan T., Genc S., Oflas U., Yuksel S., et al.

Journal of Clinical Medicine , cilt.15, sa.12, 2026 (SCI-Expanded, Scopus)

2. Prevalence of Malnutrition, Frailty, and Cachexia Across Different Cancer Subtypes: Distribution by Age (<65 and ≥65)

Kapagan T., Kılıc C. E., Arslansoy B., Yontan E., Ozcalimli Z., Ozkan Kardes B. C., et al.

Journal of Clinical Medicine , cilt.15, sa.9, 2026 (SCI-Expanded, Scopus)

3. Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study

Yolcu S. T., Günaltılı M., Yolcu E. A., Güzel S. S., Şengül N., Atcı M. M., et al.

Journal of Clinical Medicine , cilt.15, sa.7, 2026 (SCI-Expanded, Scopus)

4. Predictive Role of Serum Inflammatory Markers in Metastatic Luminal A/B Breast Cancers Receiving CDK-4/6 Inhibitors Therapy

BULUT N., Kapagan T., Ozmen A., ERDEM G. U.

Immunity, Inflammation and Disease , cilt.14, sa.4, 2026 (SCI-Expanded, Scopus)

5. Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Bedir Ş., Kapagan T., Çakan Demirel B., Tokocin M., Yıldırım Ç., Taş S., et al.

Journal of Clinical Medicine , cilt.15, sa.5, 2026 (SCI-Expanded, Scopus)

6. Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy

Bedir Ş., Yeşilova U. A., Tokoçin M., Çakan Demirel B., Bozkaya Y., Oyman A., et al.

Medicina (Lithuania) , cilt.62, sa.1, 2026 (SCI-Expanded, Scopus)

7. Can post neoadjuvant chemotherapy 18F-FDG PET/CT predict residual cancer burden in locally advanced breast cancer? La TEP/TDM au 18F-FDG postchimiothérapie néoadjuvante peut-elle prédire la charge résiduelle de cancer dans le cancer du sein localement avancé ?

Vural Topuz O., Akkurt T., ERDEM G. U., KAYA E., KAYA M., ESEN AKKAŞ B.

Medecine Nucleaire , cilt.48, sa.3, ss.141-149, 2024 (SCI-Expanded, Scopus)

8. The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas

Aydin D., KEFELİ U., ÖZÇELİK M., ERDEM G. U., Sendur M. A., Yildirim M. E., et al.

Medicina (Lithuania) , cilt.59, sa.8, 2023 (SCI-Expanded, Scopus)

9. Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?

DEMİRCİ N. S., Çavdar E., ERDEM G. U., Hatipoglu E., Celik E., Sezer S., et al.

Medicine (United States) , cilt.102, sa.25, 2023 (SCI-Expanded, Scopus)

10. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study

Erdal G. S., POLAT Ö., ERDEM G. U., Korkusuz R., HİNDİLERDEN F., Yilmaz M., et al.

International Journal of Clinical Oncology , cilt.26, sa.5, ss.826-834, 2021 (SCI-Expanded, Scopus)

11. In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review

Bozkaya Y., ERDEM G. U., DEMİRCİ N. S.

Journal of Oncology Pharmacy Practice , cilt.25, sa.3, ss.754-757, 2019 (SCI-Expanded, Scopus)

12. Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center

Bozkaya Y., Uncu D., DAĞDAŞ S., ERDEM G. U., DOĞAN M., Özet G., et al.

Indian Journal of Hematology and Blood Transfusion , cilt.33, sa.3, ss.361-369, 2017 (SCI-Expanded, Scopus)

Prof. Dr. Gökmen Umut ERDEM

Yayınlar & Eserler

1. Clinicopathological Factors Influencing Survival After Trimodality Treatment in Non-Metastatic Esophageal Cancer: A Retrospective Single-Center Study

2. Prevalence of Malnutrition, Frailty, and Cachexia Across Different Cancer Subtypes: Distribution by Age (<65 and ≥65)

3. Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study

4. Predictive Role of Serum Inflammatory Markers in Metastatic Luminal A/B Breast Cancers Receiving CDK-4/6 Inhibitors Therapy

5. Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

6. Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy

7. Can post neoadjuvant chemotherapy 18F-FDG PET/CT predict residual cancer burden in locally advanced breast cancer? La TEP/TDM au 18F-FDG postchimiothérapie néoadjuvante peut-elle prédire la charge résiduelle de cancer dans le cancer du sein localement avancé ?

8. The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas

9. Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?

10. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study

11. In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review

12. Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Tez Danışmanlığı

Açık Erişim